Application of protein marker in identification of acute pulmonary embolism complicated with pulmonary arterial hypertension model
Through the screening and verified protein marker model, combined with LRG1, LDHA, PEPD and other markers, a diagnostic model for identifying acute pulmonary embolism and pulmonary hypertension was established, which solved the identification problems in the existing technology and achieved the accuracy of patients with acute pulmonary embolism. Key tools for diagnostic and therapeutic strategy development.
Patent Information
- Application Number
- CN202411184241.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-27
AI Technical Summary
The prior art is difficult to accurately, easily and non-invasively identify whether patients with acute pulmonary embolism are complicated by pulmonary hypertension and the resulting right ventricular insufficiency, and lack of specific biomarkers, which affects diagnosis, treatment and prognosis.
Through DIA non-targeted proteomic screening and PRM-targeted proteomic verification, a Logistics diagnostic model was established based on protein markers such as LRG1, LDHA, and PEPD. LogitP=2.031*LRG1-1.524*PEPD-0.719*LDHA, used for identification Probability of acute pulmonary embolism and pulmonary hypertension.
It provides an accurate, simple and non-invasive method to identify whether patients with acute pulmonary embolism are complicated by pulmonary hypertension, helps clinicians to conduct risk stratification, formulate treatment strategies and prognostic evaluation, and improves the accuracy of diagnosis and treatment and the guiding significance of individualized treatment.
Smart Images

Figure CN119064595A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biological technology, and in particular relates to the application of protein markers in establishing a model for identifying acute pulmonary embolism complicated with pulmonary hypertension. Background Art
[0002] In acute pulmonary embolism, the increase in pulmonary artery pressure and the resulting right ventricular dysfunction are closely related to the patient's clinical deterioration and prognosis. Pulmonary hypertension caused by pulmonary embolism and subsequent right heart failure are the main causes of death. It is reported that about 35%-61% of patients have pulmonary hypertension when diagnosed with acute pulmonary embolism, and 45%-64% of patients may then develop right ventricular enlargement. The 30-day mortality rate of patients with right ventricular enlargement is about 15%, which is twice that of patients with normal pulmonary artery pressure and right ventricular diameter. Based on this, the 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism (Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603. 2019 / 09 / 11. DOI: 10.1093 / eurheartj / ehz405.) recommends pulmonary hypertension and its resulting right ventricular dysfunction as an important reference indicator in the risk stratification and treatment strategy of acute pulmonary embolism. Therefore, based on the importance of pulmonary hypertension and its resulting right ventricular dysfunction in the risk stratification, treatment strategy formulation and prognosis assessment of patients with acute pulmonary embolism, how to accurately, simply and non-invasively identify whether patients with acute pulmonary embolism have pulmonary hypertension and its resulting right ventricular dysfunction is a key link in the diagnosis and treatment of patients with acute pulmonary embolism.
[0003] At present, a variety of clinical methods can be used to evaluate pulmonary hypertension and its resulting right ventricular dysfunction, including ultrasound, magnetic resonance imaging, right cardiac catheterization and other imaging methods and biomarker detection represented by NT-proBNP. However, echocardiography is easily affected by variable factors such as cardiac structure, morphology, preload and afterload, and subjective factors of the operator, and the accuracy of judging pulmonary hypertension and its resulting right ventricular dysfunction is still a challenge; and although right cardiac catheterization and magnetic resonance imaging are the gold standard for evaluating pulmonary hypertension and its resulting right ventricular dysfunction, their clinical application is not popular due to the invasive operation characteristics or the complexity and high cost of equipment conditions, and their application is more limited when the condition of patients with acute pulmonary embolism is unstable. At this time, biomarkers, as a simple and non-invasive evaluation method, are more critical in evaluating whether patients with acute pulmonary embolism have pulmonary hypertension and its resulting right ventricular dysfunction. However, there is currently a lack of specific biomarkers related to acute pulmonary embolism complicated by pulmonary hypertension and its resulting increase in right ventricular afterload. NT-proBNP is a widely used biomarker, but it has no specificity in identifying pulmonary hypertension and its resulting right ventricular dysfunction. Therefore, it is urgent to find specific biomarkers related to acute pulmonary embolism complicated with pulmonary hypertension and its resulting right ventricular dysfunction, which can help identify the pulmonary circulation status more quickly and accurately.
[0004] The increase in pulmonary artery pressure during acute pulmonary embolism can be caused by mechanical obstruction caused by thrombus and contraction of the pulmonary vascular bed. Pulmonary vasoconstriction caused by various mechanisms largely explains why patients with acute pulmonary embolism with similar thrombus loads may present with or without pulmonary hypertension, or with varying degrees of pulmonary hypertension and the right ventricular dysfunction caused by it. Previous studies have suggested that pulmonary vasoconstriction during acute pulmonary embolism may involve multiple mechanisms and pathways, such as inflammatory response, immune response, hypoxia, platelet activation, etc. The above possible mechanisms involve a variety of biological markers and potential intervention targets, which can help clinicians better identify patients who may develop pulmonary hypertension and the right heart failure caused by it in the acute pulmonary embolism population. At the same time, treatment of related targets has important guiding significance in formulating prevention strategies for high-risk populations in the era of personalized precision medicine.
[0005] Therefore, it is necessary to develop specific biomarkers to help identify patients with acute pulmonary embolism who have pulmonary hypertension, so as to guide risk stratification and the formulation of treatment strategies, thereby improving patient prognosis. Summary of the invention
[0006] In view of this, the purpose of the present invention is to provide an application of a protein marker in identifying a model of acute pulmonary embolism complicated by pulmonary hypertension, so as to identify whether acute pulmonary embolism is complicated by pulmonary hypertension.
[0007] In order to achieve the above object, the present invention provides the use of protein markers in identifying an acute pulmonary embolism complicated by pulmonary hypertension model, wherein the protein marker combination consists of one or more of LRG1, LDHA, and PEPD.
[0008] Furthermore, the model includes the following content: LogitP=2.031*LRG1-1.524*PEPD-0.719*LDHA-0.730, where P is the probability of concurrent pulmonary hypertension.
[0009] The present invention screens out differential proteins between groups from all quantifiable proteins through DIA non-targeted proteomics, verifies through PRM targeted proteomics, and obtains protein markers that can identify acute pulmonary embolism complicated with pulmonary hypertension through ROC analysis. The above protein markers are used to establish a Logistics diagnostic model, and the regression equation is LogitP=2.031*LRG1-1.524*PEPD-0.719*LDHA-0.730, where P is the probability of complicated with pulmonary hypertension. This equation can help identify whether acute pulmonary embolism is complicated with pulmonary hypertension.
[0010] On the one hand, the present invention screened and verified three protein markers that can identify whether acute pulmonary embolism is complicated by pulmonary hypertension, and established a prediction model for pulmonary hypertension in patients with acute pulmonary embolism, which can help better identify patients who may have pulmonary hypertension or even right heart failure in the acute pulmonary embolism population, and has important guiding significance for formulating individualized treatment strategies.
[0011] The beneficial effects of the present invention are:
[0012] The application of the protein marker provided by the present invention in establishing a model for identifying acute pulmonary embolism complicated by pulmonary hypertension is based on the importance of pulmonary hypertension and the right ventricular dysfunction caused by it in the risk stratification, treatment strategy formulation and prognosis evaluation of patients with acute pulmonary embolism. The protein marker can accurately, simply and non-invasively identify whether a patient with acute pulmonary embolism has pulmonary hypertension, which is a key link in the diagnosis and treatment of acute pulmonary embolism. The present invention can help clinicians to perform risk stratification, formulate treatment strategies and evaluate prognosis of acute pulmonary embolism. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is a graph showing the differential protein results between the two groups of acute pulmonary embolism complicated with and without pulmonary hypertension obtained by DIA non-targeted proteomics screening in Example 1.
[0014] Figure 2A This is the ROC curve of LRG1 in Example 1 for identifying whether a patient with acute pulmonary embolism has pulmonary hypertension.
[0015] Figure 2BThis is the ROC curve of LDHA in Example 1 for identifying whether a patient with acute pulmonary embolism has pulmonary hypertension.
[0016] Figure 2C This is the ROC curve of PEPD in Example 1 for identifying whether a patient with acute pulmonary embolism has pulmonary hypertension.
[0017] Figure 3A This is the ROC curve of the test set of the multi-factor logistics prediction model.
[0018] Figure 3B This is the ROC curve of the validation set of the multi-factor logistics prediction model. DETAILED DESCRIPTION
[0019] The embodiments of the present invention will be described in detail and comprehensively below so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making a clearer and more definite definition of the protection scope of the present invention.
[0020] Example 1
[0021] Screening of protein markers for acute pulmonary embolism complicated by pulmonary hypertension using proteomics
[0022] 1.1 Sample Collection
[0023] The present invention collected fasting peripheral blood venous specimens from patients with acute pulmonary embolism from Fuwai Hospital of Chinese Academy of Medical Sciences and Beijing Chaoyang Hospital from July 2018 to September 2020, and all enrolled patients signed informed consent. Among them, 5 patients with acute pulmonary embolism complicated with and without pulmonary hypertension completed DIA non-targeted proteomics, and 21 patients with acute pulmonary embolism complicated with and without pulmonary hypertension completed PRM targeted proteomics.
[0024] 1.2 Sample pretreatment and storage
[0025] First, collect blood samples in 5 ml EDTA anticoagulant tubes, centrifuge at 1500g at 4°C for 15 minutes, transfer the supernatant to Eppendorf centrifuge tubes, centrifuge again at 3200g at 4°C for 15 minutes, transfer the supernatant to Eppendorf tubes again, dispense 0.5 ml / tube, add cocktail protease inhibitors at a ratio of 1:100, and store in a -80°C refrigerator.
[0026] 1.3DIA non-targeted proteomics screening of differentially expressed proteins
[0027] 1.3.1 Commercial column activation
[0028] The commercial column Pierce Top2 Abundant Protein Depletion Spin Columns (Thermo85162) was taken out from 4°C and placed on the laboratory bench to return to room temperature. The column was then flicked or gently vortexed to suspend the particles in the column.
[0029] 1.3.2 Sample incubation on column
[0030] Take 5ul of serum sample, add it to the column, flick or gently vortex to mix thoroughly, then place it in a vertical mixer and rotate and incubate at room temperature for 1 hour. During this process, the two high-peak proteins (serum albumin, IgG) in the serum sample are bound by the corresponding antibodies in the column, while the target sample components are not bound.
[0031] 1.3.3 Elution of target sample
[0032] Remove the plug from the bottom of the column, place the column in a new 1.5 ml EP tube, and centrifuge at 1000 g for 2 minutes at room temperature. The eluate is the sample with the two high peak intensities removed.
[0033] 1.3.4 Samples before FASP
[0034] The sample eluted from the column is about 400-450ul, and the solution environment is PBS.
[0035] 1.3.5 Sample FASP processing
[0036] After the sample was reduced and alkylated, it was directly added to the ultrafiltration tube of 10KD (Sartorius, VNO1H02), centrifuged at room temperature at 14000g for 15min, and the column liquid was discarded. Then 300ul of 50mM ammonium bicarbonate solution was added, centrifuged, and the column liquid was discarded as above. This was repeated for 3 times. After the last wash, a new ultrafiltration tube sleeve was replaced.
[0037] 1.3.6 Sample proteolysis
[0038] Add 300ul of 50mM ammonium bicarbonate solution to the ultrafiltration tube, then add 5μg of pancreatic enzyme, mix well, cover the opening of the ultrafiltration tube with sealing film, incubate at 37℃ for 4-6 hours, add pancreatic enzyme (5μg) again, mix well, seal, and incubate overnight.
[0039] 1.3.7 Collection of peptides by centrifugation
[0040] The next morning, the sealing film of the sample ultrafiltration tube was torn off, and the tube was centrifuged at 14000g for 16 min at room temperature. The column fluid was retained, and then 300ul of mass spectrometry water was added to the ultrafiltration tube and centrifuged as above. The column fluid was retained and the column fluid (i.e., the target peptide) eluted twice was transferred to a new 1.5ml EP tube.
[0041] 1.3.8 Peptide concentration determination
[0042] Nanodrop detected the concentration of sample peptides and calculated the mass (μg), and the blank control was mass spectrometry water.
[0043] 1.3.9 Drain and send for testing
[0044] Dry in vacuum at 60℃ and send to mass spectrometer for detection.
[0045] 1.3.10 Chromatographic conditions
[0046] Reverse phase C18 pre-column: 3 μm particle size filler, 2 cm × 100 μm inner diameter; reverse phase C18 analytical column: 1.9 μm particle size filler, 20 cm × 150 μm inner diameter; the flow rate during analysis was set to 600 nL / min, and the gradient was increased from 7% to 95% of solvent B (0.08% formic acid, 80% acetonitrile) within 90 min.
[0047] 1.3.11 Mass spectrometry conditions
[0048] The electrospray voltage was set to 2.0 kV, and a data-dependent tandem mass spectrometry method was used to analyze peptide samples, with a primary resolution of 120,000 and a secondary resolution of 15,000. The primary full scan was completed in an electrostatic field orbital ion trap (Orbitrap), with a scan range of 300-1400. The 20 ions with the highest intensity in each scan were automatically selected for fragmentation in the HCD fragmentation cell, with a fragmentation energy of 27%, and Orbitrap detection; the primary scan automatic gain control (AGC targets) was 3×e6 ions, and the maximum ion injection time (maximum injection time) was 80 ms; the secondary scan automatic gain control (AGC targets) was 5×e4 ions, and the maximum ion injection time (maximum injection time) was 40 ms; the dynamic exclusion time was set to 18 s.
[0049] 1.3.12 DIA results analysis
[0050] The R language package limma was used to compare and analyze the proteins measured using the DIA technology. The P Value < 0.05 was used as the threshold to screen differentially expressed proteins. The 22 differentially expressed proteins screened were: H2BC12, LDHA, CFB, SERPINC1, SERPINA3, C5, IGKV1D-33, C1QA, LRG1, CFI, CLEC3B, SFTPB, FCGR3A, DBH, SPP1, PEPD, DSP, LBP, SDC1, IGFBP5, CFP, TPM4. The results are as follows Figure 1 shown.
[0051] from Figure 1 It can be seen that through DIA non-targeted proteomics, compared with patients with acute pulmonary embolism without pulmonary hypertension, in patients with acute pulmonary embolism complicated by pulmonary hypertension, the levels of proteins such as H2BC12, IGFBP5, and DBH were upregulated, and the levels of proteins such as DSP, SDC1, and TPM4 were downregulated.
[0052] 1.4 PRM targeted proteomics
[0053] 1.4.1 Sample preparation
[0054] Protein extraction: Take serum samples and use High-Select TM High peak protein removal centrifugal column (ThermoScientific (Rockford, USA), A36370) was used according to the instructions to remove high peak protein. Reduction and alkylation: Add DTT to 5mM and incubate at 55℃ with shaking for 10min to reduce disulfide bonds. Cool the sample to room temperature, add IAA to 10mM and react in the dark for 15min to alkylate the reduced disulfide bonds. Transfer the reduced and alkylated sample to an ultrafiltration tube, centrifuge at 12000g, 4℃ for 30min, and discard the filtrate. Add 200μL of 0.1mmol / L TEAB solution, centrifuge at 12000g, 4℃ for 30min, discard the filtrate, and repeat three times. Wash the bottom of the ultrafiltration tube twice with 400μL of deionized water. Proteolysis: Add 100 μL of 0.1 mol / L TEAB solution to the above extract, dissolve Trypsin to 0.5 μL / μL with Resuspension buffer, incubate at room temperature for 5 min, and mix Trypsin and sample thoroughly at a ratio of Trypsin: protein = 1:50. After simple centrifugation, shake and incubate at 37℃ 1000rpm overnight. BCA quantification: Pipette BCA working solution and add it to 96-well plate, 180 μL per well, 7 standard points, and 1 blank. Add 20 μL sample to each well. Shake at 37℃ for 15 min, and detect absorbance at 480nm. Fit the standard curve according to the standard, and calculate the peptide concentration of the corresponding sample. Peptide desalting: Add 1 mL of Buffer C to the C18 column for activation, and let the whole solution flow slowly into the centrifuge tube. Add 1 mL of Buffer A for balance, and let the whole solution flow slowly into the centrifuge tube. Add the sample supernatant, let the whole solution flow slowly into the centrifuge tube, and collect the effluent (FT). Add 1mL Buffer A to rinse twice, allowing all the solution to flow slowly into the centrifuge tube. Add 400μL Buffer B to elute, and use a pipette to transfer the eluted liquid into a new EP tube (E1). Repeat the desalting of the effluent FT once (E2), and combine the two eluates (E1+E2). Vacuum dry at 4℃ overnight for later use.
[0055] 1.4.2 nanoLC-MS / MS detection
[0056] From each sample, ~1 μL of total peptide was separated by nanoUPLC liquid phase system EASYnLC1200 and then connected to a mass spectrometer (QExactive HFX) equipped with a nanoliter ion source for data acquisition. Chromatographic separation was performed using a 100 μL ID×15 cm reverse phase column (Reprosil Pur 120C18AQ, 1.9 μL, Dr. Maisch). The mobile phase used an acetonitrile-water-formic acid system, in which mobile phase A was 0.1% formic acid-98% aqueous solution (acetonitrile was 2%), and phase B was 0.1% formic acid-80% acetonitrile solution (water was 20%). After the chromatographic column was equilibrated with 100% phase A, the sample was directly loaded onto the chromatographic column by an automatic sampler, and then separated by gradient separation of the chromatographic column, with a flow rate of 300 nL / min and a gradient time of 90 min. Mobile phase B ratio: 2-5% for 2 min, 5-22% for 68 min, 22-45% for 16 min, 45-95% for 2 min, 95% for 2 min.
[0057] The mass spectrometry analysis used the parallel reaction monitoring (PRM) method and the positive ion detection mode, and the inclusion list is shown in Table 3. The quadrupole isolation window was 0.7 m / z, the normalized collision energy (NCE) was 27%, and the secondary scanning resolution was 15k.
[0058] 1.4.3 Data Analysis
[0059] The Spectra library was generated in the classic DDA data acquisition mode, combined with database search software for identification. The original data file was first converted to the mzML general file format using ProteoWizard (version 3.0.18299) software. The mass spectrometry data was searched and matched with the target protein fasta database sequence (uniprot-Human-9606-2020-10.fasta) using MSFragger1 software, and the main search parameters used the official recommended values (see philosopher.yaml for details). Enzyme specificity was set to: trypsin; allowed peptide length range: 7-50; variable modifications include: 15.994915 [M], 42.010565 [n-term]; fixed modifications include: 57.021464 [C]; parent ion mass accuracy: + / -20ppm; fragment ion accuracy: + / -20ppm. The MSFragger search results were then analyzed using the Philosopher (v3.3.11)2 toolset, which mainly included PeptideProphet and ProteinProphet (v5.2.1) for peptide and protein correct probability calculation (validation), filter for PSM, peptide, and protein FDR (1%) control, and freequant for peptide (protein) quantitative analysis.
[0060] The PRM method was constructed using Skyline software. The general process is as follows: 1) The target peptide sequence was imported into Skyline software. After setting the peptide charge and heavy isotope labeling information, the inclusion list was exported to Xcalibar software to construct the PRM method for collecting actual samples. 2) The PRM raw data was imported into Skyline software. The chromatographic peak boundary of the target peptide was determined based on the spectra and RT in Spectralibrary. When selecting secondary spectrum information, the DDA search results were given priority. 3) For each target peptide, up to multiple fragment ions were selected for quantification.
[0061] 1.4.4 Experimental results
[0062] The PRM method was used to verify that the three protein markers in the differential protein list obtained by DIA were significantly different between the acute pulmonary embolism complicated with and without pulmonary hypertension groups (with P Value < 0.05 as the threshold), including LRG1, LDHA and PEPD. FIG. 2A to FIG. 2C shown.
[0063] from FIG. 2A to FIG. 2CIt can be seen that in the ROC curve for identifying acute pulmonary embolism complicated by pulmonary hypertension, the AUC of LRG1 is 0.688, the AUC of LDHA is 0.656, and the AUC of PEPD is 0.671, which can more accurately identify patients with acute pulmonary embolism complicated by pulmonary hypertension.
[0064] From the above results, it can be seen that the AUCs of LRG1, LDHA and PEPD are all in the range of 0.6<AUC<1, which has predictive value and can be used as a single factor to identify patients with pulmonary hypertension in acute pulmonary embolism.
[0065] Example 2
[0066] Subsequently, 70% of the PRM cohort was randomly selected as a training set to establish a multifactorial logistics prediction model using the above three protein markers. The established regression equation was LogitP = 2.031*LRG1-1.524*PEPD-0.719*LDHA-0.730, and the remaining 30% was used as a test set to verify the model's prediction of the probability of pulmonary hypertension in patients with acute pulmonary embolism. The training set results are shown in Figure 2. Figure 3A The test set results are as follows Figure 3B shown.
[0067] from Figure 3A and Figure 3B It can be seen that the AUC of the logistics model constructed by combining the three protein markers of LRG1, LDHA and PEPD for identifying patients with acute pulmonary embolism complicated by pulmonary hypertension is 0.811 in the training set and 0.810 in the test set, indicating that the accuracy of identifying pulmonary hypertension in acute pulmonary embolism is closer to the extreme value of 1 of AUC perfect prediction, which is higher than the prediction accuracy of a single protein marker. The three protein markers can be used to identify people with pulmonary hypertension in acute pulmonary embolism, and the probability of occurrence of pulmonary hypertension in acute pulmonary embolism can be obtained based on the results of protein determination.
[0068] It can be seen from the above examples that the protein marker provided by the present invention is used as a substance in establishing a model for identifying acute pulmonary embolism complicated with pulmonary hypertension. Based on the plasma proteomics data of patients with acute pulmonary embolism, the protein marker associated with acute pulmonary embolism complicated with pulmonary hypertension is obtained by DIA non-targeted proteomics and PRM targeted proteomics methods, which can help clinicians to stratify the risk of acute pulmonary embolism, formulate treatment strategies and evaluate the prognosis.
[0069] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. Application of protein markers in identifying models of acute pulmonary embolism complicated with pulmonary hypertension, characterized in that: The protein marker is composed of one or more of LRG1, LDHA and PEPD.
2. The use according to claim 1, characterized in that The model includes the following content: LogitP=2.031*LRG1-1.524*PEPD-0.719*LDHA-0.730, where P is the probability of concurrent pulmonary hypertension.
